Implantable Cardioverter-Defibrillator Registry Risk Score Models for Acute Procedural Complications or Death After Implantable Cardioverter-Defibrillator Implantation

Background— Patients undergoing implantable cardioverter-defibrillator (ICD) implantation are at risk of postprocedural complications. However, we do not have a risk stratification schema to identify patients at high and low risk of adverse events. Methods and Results— We analyzed data from 268 701 ICD implants submitted to the ICD Registry and developed logistic regression models to identify variables most strongly associated with the risk of acute complications and/or in-hospital death. Overall, 3.2% of the population experienced an adverse event. A simple risk score consisting of 10 readily available variables successfully identified patients at high and low risk of complications. The variables included in the score and assigned points included: age ≥70 years (1 point), female (2 points), New York Heart Association class III (1 point) or IV (3 points), atrial fibrillation (1 point), prior valve surgery (3 points), chronic lung disease (2 points), blood urea nitrogen >30 (2 points), reimplantation for reasons other than battery change (6 points), ICD type dual chamber (2 points) or biventricular (4 points), and nonelective ICD implant (3 points). The risk of any in-hospital complication increased from 0.6% among patients with a score of ⩽5 (8.4% of the population) to 8.4% among patients with ≥19 risk points (3.9% of the population). Conclusions— A simple risk score consisting of readily available clinical variables can identify high- and low-risk subsets of patients undergoing ICD implantation. This information can guide the physician in patient selection and determining the intensity of care required post procedure.

[1]  D. Haines,et al.  Risk of Hematoma Complications After Device Implant in the Clopidogrel Era , 2010, Circulation. Arrhythmia and electrophysiology.

[2]  B. Lindsay,et al.  Review of the ICD Registry's third year, expansion to include lead data and pediatric ICD procedures, and role for measuring performance. , 2009, Heart rhythm.

[3]  K. Schulman,et al.  Patient and Implanting Physician Factors Associated With Mortality and Complications After Implantable Cardioverter-Defibrillator Implantation, 2002–2005 , 2008, Circulation. Arrhythmia and electrophysiology.

[4]  Chunliu Zhan,et al.  Cardiac Device Implantation in the United States from 1997 through 2004: A Population-based Analysis , 2007, Journal of General Internal Medicine.

[5]  D. Cohen,et al.  The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. , 2006, Journal of the American College of Cardiology.

[6]  A. Krahn,et al.  Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. , 2006, JAMA.

[7]  E. Antman,et al.  Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. , 2006, American heart journal.

[8]  D. Wennberg,et al.  The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. , 2005, Journal of the American College of Cardiology.

[9]  D. Haines,et al.  Device pocket hematoma in the clopidogrel era , 2005 .

[10]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[11]  S. Saba,et al.  Utilization of implantable cardioverter-defibrillators in survivors of cardiac arrest in the United States from 1996 to 2001. , 2004, Journal of the American College of Cardiology.

[12]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[13]  K. McDonald,et al.  Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995. , 2002, American heart journal.

[14]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[15]  B. Wilkoff,et al.  Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. , 2001, American heart journal.

[16]  B. Wilkoff,et al.  The management of surgical complications of pacemaker and implantable cardioverter-defibrillators. , 2001, Current opinion in cardiology.

[17]  E. Antman,et al.  TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.

[18]  F. Morady,et al.  A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. , 2000, Journal of the American College of Cardiology.

[19]  M Gent,et al.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.

[20]  J. Zaidan Implantable cardioverter-defibrillators. , 1999, Journal of cardiothoracic and vascular anesthesia.

[21]  M. Rosenqvist,et al.  Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. , 1998, Circulation.

[22]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[23]  R. Peters,et al.  Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. Worldwide Jewel Investigators. , 1996, Journal of the American College of Cardiology.

[24]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .